ALSPW Spineway SAS

Spineway : a week dedicated to medical excellence with more than 20 surgeons trained

Spineway : a week dedicated to medical excellence with more than 20 surgeons trained

Press release        

Ecully, November 14, 2024 – 6 p.m.

Spineway: a week dedicated to medical excellence with more than 20 surgeons trained

The Spineway Group, a , specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international surgeons in the use of the Group’s ESP cervical and lumbar prostheses. These events also enabled the Group's distributors to provide ongoing training and support for their users.

           

The week began with a Costa Rican surgeon being trained in the operating room by Pr. Lazennec (Hôpital de la Pitié-Salpêtrière, AP-HP Paris) on cervical prosthesis (CP-ESP) and lumbar prosthesis (LP-ESP).

This was followed by a training session with two Indonesian surgeons led by Pr. Rousseau (Hôpital Bichat-Beaujon – AP-HP Paris), who focused on the LP-ESP lumbar prosthesis. At the end of the day, Mexican and Costa Rican practitioners had the opportunity to discuss their experiences with disc prostheses with Dr. Thierry Marnay during a round table in Nîmes.

The Mexican practitioners continued their training by participating in several procedures with the LP-ESP lumbar disc prosthesis. These sessions were led by Dr. Guillaume Gras-Combe (CHU de Nîmes-Pôle Neurosciences) and Dr. Jean-Patrick Rakover (Clinique du Pré, Le Mans).

The week ended with a training session on anatomical specimens at IRCAD Strasbourg for all the practitioners trained in the operating room during the week. They were joined by five Spanish and three Portuguese surgeons. Led by the experts Pr. Rousseau, Dr. Gras-Combe, Dr. Javier Giner (Instituto Clavel, Madrid) and Dr. Eduardo Espinosa (Neurocirugía Barcelona), the training included theoretical and practical sessions covering the characteristics, indications and surgical approaches for the placement of ESP disc prostheses.

Spineway’s teams, including Yiyi Li (MEA & Asia-Pacific Sales Manager), Lorenzo Tamas (Latin American Sales Manager), Inès Khaoua (Europe Sales Manager), Mélody Ourdouillié (Medical Education Events Manager) and Loïc Aden (ESP Product Manager), were on hand to provide optimal support.

These exchanges between surgeons illustrate Spineway’s commitment to supporting health professionals in their training, ensuring mastery of advanced technologies in the field of spinal implants and supporting the development of its international network. Spineway thus confirms its aim of becoming a major player in less invasive spine treatments in Europe, Latin America and Asia.

Next events:

December 5, 2024 – 6 p.m. CET – Webinar – Business update

January 22, 2025 – Full-year 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060
 



AELIUM



Investor relations



Solène Kennis







Attachment



EN
14/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch